4,244 Shares in Moderna, Inc. $MRNA Bought by Machina Capital S.A.S.

Machina Capital S.A.S. purchased a new stake in Moderna, Inc. (NASDAQ:MRNA – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,244 shares of the company’s stock, valued at approximately $817,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Illinois Municipal Retirement Fund increased its stake in shares of Moderna by 12.3% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 115,726 shares of the company’s stock valued at $22,285,000 after acquiring an additional 12,721 shares during the last quarter. Philadelphia Trust Co. bought a new position in Moderna during the 3rd quarter worth approximately $410,000. Mesirow Financial Investment Management Inc. bought a new position in Moderna during the 3rd quarter worth approximately $383,000. Lido Advisors LLC grew its holdings in Moderna by 0.5% during the third quarter. Lido Advisors LLC now owns 16,605 shares of the company’s stock valued at $3,198,000 after purchasing an additional 83 shares during the period. Finally, Keybank National Association OH raised its holdings in Moderna by 5.6% in the third quarter. Keybank National Association OH now owns 9,581 shares of the company’s stock worth $1,845,000 after purchasing an additional 512 shares during the period. Institutional investors own 75.33% of the company’s stock.

Moderna Stock Performance

Shares of NASDAQ:MRNA opened at $223.37 on Monday. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $280.80. The company has a quick ratio of 3.47, a current ratio of 3.62 and a debt-to-equity ratio of 0.52. The company’s fifty day simple moving average is $201.67 and its 200 day simple moving average is $96.41. The firm has a market cap of $90.38 billion, a price-to-earnings ratio of -31.46 and a beta of 1.16.

Moderna (NASDAQ:MRNA – Get Free Report) last announced its earnings results on Friday, November 6th. The company reported $0.38 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.10) by $1.48. The firm had revenue of $1.31 billion during the quarter, compared to analyst estimates of $890.25 million. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. The company’s revenue for the quarter was up 29.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.51) EPS. As a group, research analysts forecast that Moderna, Inc. will post -5.14 EPS for the current fiscal year.

Insider Activity

In other news, insider Shannon Klinger sold 3,471 shares of the company’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the completion of the transaction, the insider directly owned 74,129 shares of the company’s stock, valued at $10,374,353.55. This represents a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 39,145 shares of the company’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $220.72, for a total value of $8,640,084.40. Following the transaction, the president directly owned 1,636,565 shares of the company’s stock, valued at $361,222,626.80. This represents a 2.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 197,251 shares of company stock worth $33,875,904 over the last three months. Corporate insiders own 10.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Evercore lifted their price target on shares of Moderna from $50.00 to $80.00 in a research report on Thursday, October 8th. Barclays raised their price objective on Moderna from $48.00 to $125.00 and gave the stock an “equal weight” rating in a research note on Monday, August 24th. Jefferies Financial Group reiterated a “hold” rating and set a $150.00 target price (up from $60.00) on shares of Moderna in a report on Wednesday, August 19th. Wolfe Research raised Moderna from an “underperform” rating to a “peer perform” rating in a research note on Tuesday, August 25th. Finally, Brookline Capital Markets restated a “buy” rating on shares of Moderna in a report on Wednesday, August 19th. Six research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $113.75.

View Our Latest Research Report on MRNA

More Moderna News

Investors following MRNA have been watching these news items:

  • Positive Sentiment: Moderna lifted its 2026 revenue-growth forecast to 15%–25%, from a previous outlook of up to 10%, citing commercial progress including stronger overseas COVID-19 sales. Article
  • Neutral Sentiment: Moderna is scheduled to join the MSCI World Index in November, which could broaden its investor reach. It also reported peer-reviewed real-world data on its mNEXSPIKE COVID-19 vaccine in older adults; the reports provided limited detail on the potential commercial impact. Article
  • Negative Sentiment: Investors are concerned about roughly $4 billion in planned 2027 cash costs, much of it tied to pipeline investment, while visibility into future revenue growth remains limited. Coverage also noted that the 2026 revenue outlook may fall short of analyst expectations, tempering the more optimistic growth forecast. Article

Moderna Profile

(Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

Featured Articles

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.